| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Methoxypyridine-3-boronic acid does not have a defined primary drug target as it is a chemical reagent and synthetic building block rather than a therapeutic agent. Boronic acid-containing compounds have been extensively studied as proteasome inhibitors and enzyme inhibitors. The pyridine ring is a common pharmacophore in medicinal chemistry, and the methoxy group can modulate electronic properties and hydrogen bonding. Compounds synthesized using this boronic acid as a building block may target various enzymes, but the reagent itself is not a pharmacologically active agent.
|
|---|---|
| ln Vitro |
As a synthetic reagent, 2-Methoxypyridine-3-boronic acid is not typically evaluated for direct in vitro biological activity against specific molecular targets. Boronic acids in general can interact with diols and carbohydrate moieties, and some derivatives exhibit enzyme inhibitory activity. However, the parent compound is used primarily as a chemical tool rather than a bioactive molecule. Its activity in biological assays would depend on the specific context and concentration, and any observed effects are generally considered incidental.
|
| ln Vivo |
In vivo activity data for 2-Methoxypyridine-3-boronic acid itself is not available, as the compound is not intended for therapeutic use. Drug candidates synthesized using this boronic acid as a building block may be evaluated in animal models for various indications, but the biological activity is attributed to the final drug molecule rather than the boronic acid reagent. The compound's primary applications remain in chemical synthesis and medicinal chemistry research.
|
| Enzyme Assay |
Cell-free biochemical assays involving 2-Methoxypyridine-3-boronic acid typically focus on its use as a reagent in Suzuki-Miyaura coupling reactions. A standard protocol involves mixing the boronic acid with an aryl halide, a palladium catalyst (e.g., Pd(PPh₃)₄ or PdCl₂(dppf)), and a base (e.g., K₂CO₃ or Cs₂CO₃) in an appropriate solvent such as THF, dioxane, or DMF/water mixture. The reaction is typically heated to 80-100°C for several hours under inert atmosphere. The boronic acid may exist as a mixture containing varying amounts of anhydride. Reactions are monitored by TLC or HPLC and products are characterized by NMR and mass spectrometry.
|
| Cell Assay |
Cell-based assays are not typically performed with 2-Methoxypyridine-3-boronic acid as the compound is a chemical reagent. For drug molecules synthesized using this reagent, standard cell-based protocols would apply depending on the target indication. For example, cancer cell lines may be treated with the synthesized compound at concentrations ranging from 0.1-100 μM for 24-72 hours, and cell viability assessed by MTT or CellTiter-Glo assays. The boronic acid reagent itself may be used as a control to confirm that observed activity is due to the final compound structure.
|
| Animal Protocol |
In vivo studies are not typically conducted with 2-Methoxypyridine-3-boronic acid itself. For drug candidates synthesized using this reagent, standard in vivo efficacy studies involve rodent models of the target disease. A typical protocol includes oral or intravenous administration of the test compound at various doses. The boronic acid moiety in drug molecules can contribute to target engagement through reversible covalent binding to active-site residues. The pyridine ring may influence the overall pharmacokinetic and pharmacodynamic profile.
|
| ADME/Pharmacokinetics |
As a chemical reagent rather than a drug, comprehensive pharmacokinetic data for 2-Methoxypyridine-3-boronic acid is not available. The compound's molecular weight is 152.95 g/mol. The boronic acid may exist as a mixture containing varying amounts of anhydride. For drug molecules containing boronic acid moieties, PK parameters depend on the overall molecular structure and are determined empirically. The methoxy group and pyridine nitrogen may influence metabolic stability and protein binding.
|
| Toxicity/Toxicokinetics |
Toxicological data specific to 2-Methoxypyridine-3-boronic acid is limited. As with all boronic acids and chemical reagents, standard laboratory safety precautions should be observed when handling this compound. The compound may cause irritation upon skin or eye contact. For drug candidates synthesized using this reagent, comprehensive toxicological evaluation is required as part of the drug development process.
|
| Additional Infomation |
2-Methoxypyridine-3-boronic acid is a research chemical and synthetic reagent rather than an approved pharmaceutical agent. No clinical trials or regulatory approvals exist for this compound itself. It is commercially available from various chemical suppliers for research purposes only. The compound's primary value lies in its utility as a versatile building block in Suzuki-Miyaura cross-coupling reactions for the synthesis of biaryls and other complex organic molecules. The methoxy-substituted pyridine boronic acid provides unique electronic and steric properties for selective coupling reactions, making it a valuable intermediate for pharmaceutical synthesis and medicinal chemistry research.
|
| Molecular Formula |
C6H8BNO3
|
|---|---|
| Molecular Weight |
152.94
|
| Exact Mass |
153.059
|
| CAS # |
163105-90-6
|
| PubChem CID |
2762709
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
326.4±52.0 °C at 760 mmHg
|
| Melting Point |
136-138°C
|
| Flash Point |
151.2±30.7 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.524
|
| LogP |
0.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C(B(O[H])O[H])C([H])=C([H])C([H])=N1
|
| InChi Key |
NVOLYUXUHWBCRJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H8BNO3/c1-11-6-5(7(9)10)3-2-4-8-6/h2-4,9-10H,1H3
|
| Chemical Name |
(2-methoxypyridin-3-yl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5385 mL | 32.6926 mL | 65.3851 mL | |
| 5 mM | 1.3077 mL | 6.5385 mL | 13.0770 mL | |
| 10 mM | 0.6539 mL | 3.2693 mL | 6.5385 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
